MetaVia Revenue
Biotechnology Research • 
Cambridge, Massachusetts, United States • 11-20 Employees
MetaVia revenue & valuation
| Annual revenue | $1,026,660 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $3,300,000 |
| Total funding | $10,000,000 |
Key Contacts at MetaVia
Hyung Heon Kim
Chief Executive Officer
Jean Lee
Director Of Clinical Science
Gordon Strickland
Member Board Of Directors And Chair Of The Audit Committee
Company overview
| Headquarters | 545 Concord Ave, Cambridge, Massachusetts 02138, US |
| Phone number | +18577029600 |
| Websites | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Diabetes, Obesity, Cardiometabolic Diseases, Mash |
| Founded | 2017 |
| Employees | 11-20 |
| Socials |
MetaVia Email Formats
MetaVia uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 42.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name}@company.com | john.doe@company.com | 42.1% |
{first name}@company.com | john@company.com | 25.3% |
{first name initial}{last name}@company.com | {first name initial}doe@company.com | 14.8% |
{first name}{last name}@company.com | johndoe@company.com | 10.2% |
{last name}@company.com | doe@company.com | 7.6% |
About MetaVia
MetaVia (Nasdaq: MTVA) is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for once-a-week injection. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. Our strategic partner and the largest investor, Dong-A ST Co. Ltd., is part of the Dong-A Socio Group of companies established in 1932 and based in South Korea. MetaVia has the full support of Dong-A ST’s Research Center, providing the company with access to R&D, scientific and CMC expertise.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
MetaVia has 5 employees across 4 departments.
Departments
Number of employees
MetaVia Tech Stack
Discover the technologies and tools that power MetaVia's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
JavaScript libraries
CMS
JavaScript libraries
JavaScript libraries
Maps
Security
Security
JavaScript libraries
CDN
Programming languages
Security
Germany
Australia
Qatar
Frequently asked questions
4.8
40,000 users
